Table 1. Leishmania vaccine antigens being tested as candidate DNA vaccines.
Candidate antigen | Models | Disease | Species | Reference |
---|---|---|---|---|
LACK | Dog, mice | VL, CL | L. donovani, L. chagasi, L. major, L. infantum | 86, 87, 88, 89, 90 |
gp63 | Mice, dogs | CL, VL | L. major, L. infantum | 88, 90 |
KMP11 | Mice | CL, VL | L. major L. donovani | 91, 92, 93 |
CPB | Dogs, mice | VL, CL | L. infantum, L. major | 94, 95 |
ORFF | Mice | VL | L. donovani | 96 |
NH 36 | Mice | VL, CL | L. chagasi, L. maxicana | 97, 98 |
TRYP | Dogs | VL | L. infantum | 90 |
PSA-2 | Mice | CL | L. major | 88 |
Abbreviations: CPB, cysteine proteinase B; CL, cutaneous leishmaniasis; gp63, glycoprotein 63; KMP11, kinetoplastid membrane protein-11; LACK, Leishmania-activated C kinase; NH36, nucleoside hydrolase 36; ORFF, open reading frame F; PSA-2, promastigote surface antigen 2; TRYP, tryparedoxin peroxidase; VL, visceral leishmaniasis.